CR20230464A - Dominios de unión a pd-1 novedosos. - Google Patents
Dominios de unión a pd-1 novedosos.Info
- Publication number
- CR20230464A CR20230464A CR20230464A CR20230464A CR20230464A CR 20230464 A CR20230464 A CR 20230464A CR 20230464 A CR20230464 A CR 20230464A CR 20230464 A CR20230464 A CR 20230464A CR 20230464 A CR20230464 A CR 20230464A
- Authority
- CR
- Costa Rica
- Prior art keywords
- binding
- present disclosure
- binding domains
- novel
- disclosure further
- Prior art date
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 7
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000048362 human PDCD1 Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a dominios de unión a PD-1 novedosos que tienen una mayor afinidad de unión por PD-1 humana que un dominio de unión a PD-1 de referencia. Los dominios de unión a PD-1 de la presente divulgación proporcionan además una potencia comparable, igual o mayor en el bloqueo de la unión de ligandos a PD-1 humana que un anticuerpo PD-1 de referencia. La presente divulgación se refiere además a porciones de unión que comprenden dichos dominios de unión a PD-1. También se proporciona un método para tratar una enfermedad, en particular una enfermedad asociada con un sistema inmunitario suprimido, tal como el cáncer, con un dominio de unión a PD-1 o una porción de unión de la presente divulgación. La presente divulgación se refiere además a ácidos nucleicos que codifican la región variable de cadena pesada de los dominios de unión a PD-1, y a un vector y una célula que comprenden dicho ácido nucleico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2027892 | 2021-03-31 | ||
| PCT/NL2022/050178 WO2022211629A1 (en) | 2021-03-31 | 2022-03-31 | Novel pd-1 binding domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230464A true CR20230464A (es) | 2023-11-30 |
Family
ID=76159949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230464A CR20230464A (es) | 2021-03-31 | 2022-03-31 | Dominios de unión a pd-1 novedosos. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11993654B2 (es) |
| EP (1) | EP4314062A1 (es) |
| JP (1) | JP2024511589A (es) |
| KR (1) | KR20230163503A (es) |
| CN (2) | CN117677635A (es) |
| AU (1) | AU2022248913A1 (es) |
| CA (1) | CA3211727A1 (es) |
| CL (1) | CL2023002930A1 (es) |
| CO (1) | CO2023012818A2 (es) |
| CR (1) | CR20230464A (es) |
| EC (1) | ECSP23074485A (es) |
| IL (1) | IL307316A (es) |
| MX (1) | MX2023011663A (es) |
| PE (1) | PE20241732A1 (es) |
| TW (1) | TW202304995A (es) |
| WO (1) | WO2022211629A1 (es) |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| LT2699264T (lt) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1 |
| US9701749B2 (en) | 2011-08-11 | 2017-07-11 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising PD-1 agonist |
| WO2016011069A1 (en) | 2014-07-15 | 2016-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of cd38 agonists (antibodies) |
| US11124569B2 (en) | 2015-09-18 | 2021-09-21 | Dana-Farber Cancer Institute, Inc. | Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors |
| US10981991B2 (en) | 2015-09-29 | 2021-04-20 | Shanghai Zhangjiang Biotechnology Co., Ltd. | PD-1 antibodies and uses thereof |
| RU2656181C1 (ru) * | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| RU2725950C1 (ru) * | 2016-08-05 | 2020-07-07 | И-Байолоджикс Инк. | Антитела против белка-1 запрограммированной клеточной смерти (pd-1) и их применение |
| US10793632B2 (en) * | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| JP2019534859A (ja) | 2016-09-19 | 2019-12-05 | セルジーン コーポレイション | Ｐｄ−１結合タンパク質を使用して白斑を治療する方法 |
| MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
| WO2018127711A1 (en) * | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single Domain Antibodies to Programmed Cell Death (PD-1) |
| WO2018162944A1 (en) * | 2017-03-04 | 2018-09-13 | Shenzhen Runshin Bioscience | Recombinant antibodies to programmed death 1 (pd-1) and uses therefor |
| KR102715567B1 (ko) * | 2017-07-06 | 2024-10-14 | 메뤼스 엔.페. | 세포에 의해 발현된 생물학적 활성을 조정하는 결합 분자 |
| EA202090005A1 (ru) | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Антитела, модулирующие биологическую активность, проявляемую клеткой |
| WO2019204132A1 (en) * | 2018-04-15 | 2019-10-24 | Biosion Inc. | Antibodies binding pd-1 and uses thereof |
| WO2019201169A1 (en) * | 2018-04-15 | 2019-10-24 | Salubris (Chengdu) Biotech Co., Ltd | Antibodies binding pd-1 and uses thereof |
| JP7535503B2 (ja) * | 2018-05-17 | 2024-08-16 | ナンジン リーズ バイオラブズ カンパニー リミテッド | Ｐｄ－１に結合する抗体及びその使用 |
| CN112424231B (zh) * | 2018-07-19 | 2022-09-13 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其剂量和用途 |
| CN111349162A (zh) * | 2018-12-21 | 2020-06-30 | 神州细胞工程有限公司 | 人源化抗pd-1抗体及其用途 |
| WO2021243028A1 (en) | 2020-05-27 | 2021-12-02 | Dana-Farber Cancer Institute, Inc. | Bispecific molecules for selectively modulating t cells |
-
2022
- 2022-03-31 KR KR1020237037163A patent/KR20230163503A/ko active Pending
- 2022-03-31 EP EP22715207.1A patent/EP4314062A1/en active Pending
- 2022-03-31 CN CN202280026549.0A patent/CN117677635A/zh active Pending
- 2022-03-31 US US17/710,243 patent/US11993654B2/en active Active
- 2022-03-31 PE PE2023002766A patent/PE20241732A1/es unknown
- 2022-03-31 JP JP2023555837A patent/JP2024511589A/ja active Pending
- 2022-03-31 TW TW111112618A patent/TW202304995A/zh unknown
- 2022-03-31 AU AU2022248913A patent/AU2022248913A1/en active Pending
- 2022-03-31 MX MX2023011663A patent/MX2023011663A/es unknown
- 2022-03-31 WO PCT/NL2022/050178 patent/WO2022211629A1/en active Application Filing
- 2022-03-31 CN CN202410403186.9A patent/CN118146374A/zh active Pending
- 2022-03-31 CA CA3211727A patent/CA3211727A1/en active Pending
- 2022-03-31 CR CR20230464A patent/CR20230464A/es unknown
- 2022-03-31 IL IL307316A patent/IL307316A/en unknown
-
2023
- 2023-09-27 CO CONC2023/0012818A patent/CO2023012818A2/es unknown
- 2023-09-29 EC ECSENADI202374485A patent/ECSP23074485A/es unknown
- 2023-09-29 CL CL2023002930A patent/CL2023002930A1/es unknown
-
2024
- 2024-04-03 US US18/625,756 patent/US20240425595A1/en active Pending
- 2024-04-03 US US18/625,703 patent/US20240425594A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117677635A (zh) | 2024-03-08 |
| AU2022248913A1 (en) | 2023-11-02 |
| KR20230163503A (ko) | 2023-11-30 |
| JP2024511589A (ja) | 2024-03-14 |
| EP4314062A1 (en) | 2024-02-07 |
| PE20241732A1 (es) | 2024-08-19 |
| MX2023011663A (es) | 2023-10-11 |
| US11993654B2 (en) | 2024-05-28 |
| CO2023012818A2 (es) | 2023-12-20 |
| IL307316A (en) | 2023-11-01 |
| WO2022211629A1 (en) | 2022-10-06 |
| CL2023002930A1 (es) | 2024-02-16 |
| CA3211727A1 (en) | 2022-10-06 |
| TW202304995A (zh) | 2023-02-01 |
| CN118146374A (zh) | 2024-06-07 |
| ECSP23074485A (es) | 2023-12-29 |
| US20230036061A1 (en) | 2023-02-02 |
| US20240425594A1 (en) | 2024-12-26 |
| US20240425595A1 (en) | 2024-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552122A1 (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
| MX2023005375A (es) | Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. | |
| MX337052B (es) | Peptidos que se enlazan a fosfatidiletanolamina y sus usos en el tratamiento de infecciones virales y del cancer. | |
| PH12022500024A1 (en) | Immune activating fc domain binding molecules | |
| NZ595792A (en) | Antibodies specific to cadherin-17 | |
| PH12022500027A1 (en) | Antibodies binding to cd3 | |
| MX2021009975A (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. | |
| WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
| WO2022032003A3 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| CR20220637A (es) | Anticuerpos que se unen a cd3 y cd19 | |
| MX2020009743A (es) | Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos. | |
| MX2022015475A (es) | Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma. | |
| CR20230025A (es) | Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas | |
| MX2023011663A (es) | Dominios de union a pd-1 novedosos. | |
| PH12023552704A1 (en) | Novel multispecific antibodies | |
| PH12023552740A1 (en) | Multispecific Binding Moieties Comprising Novel PD-1 Binding Domains | |
| MX2021004504A (es) | Anti-familia con similitud de secuencia 19, anticuerpos del miembro a5 y método de uso de los mismos. | |
| MX2023014666A (es) | Agentes aglutinantes biespecificos que se unen a cldn18.2 y cd3. | |
| MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
| MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. | |
| He et al. | Purified anti-CD3× anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells | |
| MX2023015442A (es) | Tratamiento de la enfermedad cardiovascular con proteínas de unión a antígeno trem-1. | |
| PH12022550006A1 (en) | Cd38-binding agents and uses thereof | |
| WO2023038803A3 (en) | Engineered anti-her2 bispecific proteins | |
| WO2024027764A3 (en) | Chimeric antigen receptor systems, methods of preparation, and uses thereof |